Rivastigmine tartrate reduces cognitive decline of people with mild to moderate Alzheimer's disease

November 08, 2000

Results of a 52-week study published in the November issue of European Neurology, which shows that rivastigmine tartrate reduces the cognitive decline of people with mild to moderate Alzheimer's disease, were reported by Martin R. Farlow, professor and vice chairman for research, Department of Neurology, Indiana University School of Medicine.

Rivastigmine is a cholinesterase inhibitor marketed as Exelon® by the Novartis Pharmaceuticals Corp.

Dr. Farlow found that patients treated daily with 6 mg. to 12 mg. of rivastigmine had significantly better cognitive function over the course of 52 weeks than patients originally treated with placebo or who received lower doses of the drug.

The study was conducted in two phases. The first phase was a randomized, double-blind, placebo-controlled trial of 26-weeks duration. In the second phase, all patients were progressively increased to their maximum tolerated dosage, even those originally on placebo, up to 12 mg. a day.

"The original placebo patients who were switched to rivastigmine showed significant cognitive improvement, but did not quite catch up to the patients treated with 6 to 12 mg. daily from the start," said Dr. Farlow.

The effects of the treatment were assessed by evaluating patients with the Alzheimer Disease Assessment Scale - Cognitive Subscale (ADAS-Cog).

Patients treated with placebo during the 26-week trial, had a mean decline of 3.8 ADAS-Cog points. There were 545 patients who completed the initial phase of the trial and 532 then agreed to enter the six-month, open-label extension trial.

By the end of this 52-week trial, patients who originally received placebo during the first 26 weeks scored less improvement on the ADAS-Cog test than patients who received rivastigmine during the entire 52-week period. Patients who received the higher dose of rivastigmine from the beginning had higher ADAS-Cog scores at the end than either the original placebo or low-dose rivastigmine groups.

"This study suggests that early treatment with 6 to 12 mg. daily of rivastigmine may provide benefits that are lost if treatment is delayed," said Dr. Farlow. "The failure of delayed treatment to give the same benefits of earlier therapy is evidence that suggests rivastigmine may affect the biological progression of the disease."
-end-
This clinical trial was supported by Novartis and conducted at 22 sites across the United States.

Indiana University

Related Cognitive Decline Articles from Brightsurf:

Actively speaking two languages protects against cognitive decline
According to a study led by Marco Calabria, a researcher of the Speech Production and Bilingualism research group and of the Cognitive NeuroLab at the UOC, the diagnosis of mild cognitive impairment in Alzheimer patients with a higher degree of bilingualism is delayed.

Metformin treatment linked to slowed cognitive decline
A six-year study of older Australians with type 2 diabetes has uncovered a link between metformin use, slower cognitive decline and lower dementia rates.

Examining association between sleep duration, cognitive decline
Researchers in this observational study investigated the association between the amount of sleep at night and cognitive decline among participants in two large studies on aging.

Lifestyle improvements may lessen cognitive decline
Results from a new study suggest that lifestyle changes may help to improve cognition in older adults experiencing cognitive decline that precedes dementia.

Baby boomers show concerning decline in cognitive functioning
In a reversal of trends, American baby boomers scored lower on a test of cognitive functioning than did members of previous generations, according to a new nationwide study.

Memory loss reversed or abated in those with cognitive decline
Affirmativ Health sought to determine whether a comprehensive and personalized program, designed to mitigate risk factors of Alzheimer's disease could improve cognitive and metabolic function in individuals experiencing cognitive decline.

Delirium may cause long term cognitive decline
A new meta-analysis of 24 observational studies from researchers at Columbia University Vagelos College of Physicians and Surgeons found that delirium may cause significant long-term cognitive decline.

Is delirium associated with long-term cognitive decline?
The results of 23 studies were combined to examine whether an episode of delirium is a risk factor for long-term cognitive decline.

Maintaining heart health may protect against cognitive decline
People with a higher risk of developing cardiovascular disease have increased cognitive decline, including an increase in typical markers of Alzheimer's disease, suggesting that monitoring and controlling for heart disease may be key to maintaining and improving cognitive health later in life, according to research published today in the Journal of the American College of Cardiology.

Hearing aids may delay cognitive decline, research finds
Wearing hearing aids may delay cognitive decline in older adults and improve brain function, according to promising new research.

Read More: Cognitive Decline News and Cognitive Decline Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.